Response to 5‐azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy‐related myelodysplastic syndrome

No abstract is available for this paper.

• Publication year

  2011

• Venue

  British Journal of Haematology

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2141.2010.08438.xPMID 21332703
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.

  2010cited by this paper
• Aberrant DNA methylation is a dominant mechanism in MDS progression to AML.

  2009cited by this paper
• MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.

  2009cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009influential reference
• Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes

  2009cited by this paper
• Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

  2009cited by this paper
• Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype

  2008cited by this paper
• CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine

  2007cited by this paper
• Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

  2007cited by this paper
• Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma.

  2006cited by this paper
• Valproic acid

  1980cited by this paper

• Advances in Hodgkin Lymphoma Treatment: From Molecular Biology to Clinical Practice

  2024cites this paper
• New molecular targets in Hodgkin and Reed-Sternberg cells

  2023cites this paper
• Deregulated miRNAs Contribute to Silencing of B-Cell Specific Transcription Factors and Activation of NF-κB in Classical Hodgkin Lymphoma

  2021cites this paper
• SMAD1 promoter hypermethylation and lack of SMAD1 expression in Hodgkin lymphoma: a potential target for hypomethylating drug therapy

  2020cites this paper
• Erhöhung der Sensitivität des klassischen Hodgkin Lymphoms auf epigenetische Therapie

  2019influential citation
• Activation of oncogenic pathways in classical Hodgkin lymphoma by decitabine: A rationale for combination with small molecular weight inhibitors.

  2017cites this paper
• Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models.

  2013cites this paper
• Outcome of therapy-related myeloid neoplasms treated with azacitidine

  2012cites this paper